The era
of guessing
is over.

Pepper Bio develops cures with confidence.

Find new targets. Predict the best patients. And know how well new drugs will work, before you begin. Applying transomic technology that uses phosphoproteomic data, Pepper creates treatments for previously untreatable diseases with more informed drug discovery and development.

The End of Untreatable.

Pepper has produced concrete results: proofs of concept across three therapeutic areas powering better drug discovery.

The End of Untreatable.

Pepper has produced concrete results: proofs of concept across three therapeutic areas powering better drug discovery.

Neurodegenerative

Currently working with a paid industry partner on a drug mechanism of action study.

Publication pending

Oncology

Pre-clinical discovery in untreatable cancers to create a proprietary disease database using transomic data.

Published in Cell Systems (Brubaker, et al., 2019) and Cancer Discovery (Poulin, et al., 2019)
Inflammatory

Pre-clinical validation with an industry partner for indication expansion into IBD from RA.

Published in Integrative Biology (Strasser, et al., 2019) and Science Signaling (Lyons, et al., 2018)
Neurodegenerative

Currently working with a paid industry partner on a drug mechanism of action study.

Publication pending

Inflammatory

Pre-clinical validation with an industry partner for indication expansion into IBD from RA.

Published in Integrative Biology (Strasser, et al., 2019) and Science Signaling (Lyons, et al., 2018)
Oncology

Pre-clinical discovery in untreatable cancers to create a proprietary disease database using transomic data.

Published in Cell Systems (Brubaker, et al., 2019) and Cancer Discovery (Poulin, et al., 2019)

Transomics changes what’s possible.

Global

Capture the full picture of disease biology and drug mechanism with global omic data.

Functional

See the reality of biological processes thanks to proteomic and phosphoproteomic data.

Causative

Understand actual drivers — not just correlation — with Pepper’s integrated analysis.

Our platform is the first to use a truly transomic analysis — integrating phosphoproteomics, proteomics, transcriptomics, and genomics. This whole-stack solution to common drug discovery challenges reveals actionable insights others miss.

Transomics changes what’s possible.

Global

Capture the full picture of disease biology and drug mechanism with global omic data.

Functional

See the reality of biological processes thanks to proteomic and phosphoproteomic data.

Causative
Understand actual drivers — not just correlation — with Pepper’s integrated analysis.

Our platform is the first to use a truly transomic analysis — integrating phosphoproteomics, proteomics, transcriptomics, and genomics. This whole-stack solution to common drug discovery challenges reveals actionable insights others miss.

Leveraging new data to develop new cures.

Novel drug development

End-to-end drug discovery

Repeatable development process

Unlock greater commercial opportunities.

Biomarker identification

Target identification

Indication expansion

Drug combinations

Patient stratification

Lead optimization

Pepper’s solutions identify new possibilities for advancing your business. We partner with your R&D teams, showing you where to start — and just how far you can go. It’s an engine for reliable, repeatable commercial success.

Leveraging new data to develop new cures.

Novel drug development

End-to-end drug discovery

Repeatable development process

Unlock greater commercial opportunities.

Biomarker identification

Drug combinations

Target identification

Patient stratification

Indication expansion

Lead optimization

Pepper’s solutions identify new possibilities for advancing your business. We partner with your R&D teams, showing you where to start — and just how far you can go. It’s an engine for reliable, repeatable commercial success.

We’re bridging data, biology, and business.

Samantha Dale
Strasser, PhD

CSO & Co-Founder
PhD, MIT

Samantha develops Pepper’s technology. An NSF Graduate Research Fellow, Churchill Scholar, and Goldwater Scholar, she pioneered omics analysis approaches in Electrical Engineering and Computer Science as well as Biological Engineering at MIT, mentored by Douglas Lauffenburger.

Jon Hu

CEO & Co-Founder
MBA, Harvard Business School

Jon leads Pepper’s business operations. Prior to co-founding Pepper, he served as CEO of enterprise solutions Guild portfolio company Atidiv, where he grew the team from 200 to 300 people, as well as COO of the tech conference Techweek.

Christopher
Nicholson, PhD

Head, Biology
PhD, Newcastle University

Christopher heads Pepper’s research strategy. He was previously a Senior Research Fellow at Harvard Medical School and MGH.

Caitlin Brown, PhD

Head, Business Development
PhD, Brown University

Caitlin heads Pepper's business development. Before joining Pepper, she was a postdoctoral fellow at UMass Medical School and an associate on Cowen's healthcare equity research team.

Arudhir Singh

Senior Platform Engineer
BS, University of Illinois at Urbana-Champaign

Aru leads development of Pepper’s platform. Before joining Pepper, he worked as an organism engineer and computational biologist at Ginkgo Bioworks.

 

Mentored by longtime pharma luminaries.

Douglas Lauffenburger, PhD

  • Professor, MIT
  • Founder, Biological Engineering, MIT

Dean Felsher,
MD, PhD

  • Professor, Oncology, Stanford
  • Director, Translational Research,
    Stanford

Imran Nasrullah,
JD

  • VP & Head, Open Innovation Center North America – East, Bayer
  • Former Director, Strategic Partnering
    & Business Development & Licensing, Boehringer-Ingelheim

Tom Rush,
PhD

  • Chief R&D Officer, Variant Bio
  • Former US Lead, Functional Genomics, GlaxoSmithKline

Peter Hornbeck,
PhD

  • Director, Cell Signaling Technology
  • Founder, PhosphoSitePlus

We’re bridging data, biology, and business.

Samantha Dale Strasser, PhD

CSO & Co-Founder
PhD, MIT

Samantha develops Pepper’s technology.  An NSF Graduate Research Fellow, Churchill Scholar, and Goldwater Scholar, she pioneered omics analysis approaches in Electrical Engineering and Computer Science as well as Biological Engineering at MIT, mentored by Douglas Lauffenburger.

Jon Hu

CEO & Co-Founder
MBA, Harvard Business School

Jon leads Pepper’s business operations. Prior to co-founding Pepper, he served as CEO of enterprise solutions Guild portfolio company Atidiv, where he grew the team from 200 to 300 people, as well as COO of the tech conference Techweek.

Christopher Nicholson, PhD

Head, Biology
PhD, Newcastle University

Christopher heads Pepper’s research strategy. He was previously a Senior Research Fellow at Harvard Medical School and MGH.


Caitlin Brown, PhD

Head, Business Development
PhD, Brown University

Caitlin heads Pepper's business development. Before joining Pepper, she was a postdoctoral fellow at UMass Medical School and an associate on Cowen's healthcare equity research team.

Arudhir Singh

Senior Platform Engineer
BS, University of Illinois at Urbana-Champaign

Aru leads development of Pepper’s platform. Before joining Pepper, he worked as an organism engineer and computational biologist at Ginkgo Bioworks.

Mentored by longtime pharma luminaries.

Douglas Lauffenburger, PhD

  • Professor, MIT
  • Founder, Biological Engineering, MIT

Dean Felsher, MD, PhD

  • Professor, Oncology, Stanford
  • Director, Translational Research,
    Stanford

Imran Nasrullah, JD

  • VP & Head, Open Innovation Center North America – East, Bayer
  • Former Director, Strategic Partnering
    & Business Development & Licensing, Boehringer-Ingelheim

Tom Rush, PhD

  • Chief R&D Officer, Variant Bio
  • Former US Lead, Functional Genomics, GlaxoSmithKline

Peter Hornbeck, PhD

  • Director, Cell Signaling Technology
  • Founder, PhosphoSitePlus

Join the transomic era of drug discovery and development.

Contact us to learn how you can work with Pepper. Send us a message, and a member of our team will reach out to you shortly.